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Abstract
P-glycoprotein (Pgp) extrudes a large variety of chemotherapeutic drugs from the cells, causing multidrug resistance (MDR).
The UIC2 monoclonal antibody recognizes human Pgp and inhibits its drug transport activity. However, this inhibition is
partial, since UIC2 binds only to 10–40% of cell surface Pgps, while the rest becomes accessible to this antibody only in the
presence of certain substrates or modulators (e.g. cyclosporine A (CsA)). The combined addition of UIC2 and 10 times lower
concentrations of CsA than what is necessary for Pgp inhibition when the modulator is applied alone, decreased the EC50 of
doxorubicin (DOX) in KB-V1 (Pgp+) cells in vitro almost to the level of KB-3-1 (Pgp-) cells. At the same time, UIC2 alone did
not affect the EC50 value of DOX significantly. In xenotransplanted severe combined immunodeficient (SCID) mice co-
treated with DOX, UIC2 and CsA, the average weight of Pgp+ tumors was only,10% of the untreated control and in 52% of
these animals we could not detect tumors at all, while DOX treatment alone did not decrease the weight of Pgp+ tumors.
These data were confirmed by visualizing the tumors in vivo by positron emission tomography (PET) based on their
increased 18FDG accumulation. Unexpectedly, UIC2+DOX treatment also decreased the size of tumors compared to the DOX
only treated animals, as opposed to the results of our in vitro cytotoxicity assays, suggesting that immunological factors are
also involved in the antitumor effect of in vivo UIC2 treatment. Since UIC2 binding itself did not affect the viability of Pgp
expressing cells, but it triggered in vitro cell killing by peripheral blood mononuclear cells (PBMCs), it is concluded that the
impressive in vivo anti-tumor effect of the DOX-UIC2-CsA treatment is the combined result of Pgp inhibition and antibody
dependent cell-mediated cytotoxicity (ADCC).
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Introduction
One of the most common causes of cancer chemotherapy
failure is the development of resistance against chemotherapeutic
agents. In most cases the tumor cells are either intrinsically
resistant, or become resistant in the course of chemotherapy, to a
broad spectrum of chemotherapeutic agents, including compounds
they have never met before [1]. This phenomenon is called
multidrug resistance (MDR) and it is often associated with high-
level expression of active transporter proteins belonging to the
ATP Binding Cassette (ABC) super-family, such as ABCB1
(MDR1, P-glycoprotein, Pgp), ABCC1 (MRP1, multidrug resis-
tance protein 1) or ABCG2 (BCRP, breast cancer resistance
protein)[2,3]. Pgp was the first transporter described in connection
with multidrug resistance, and it seems to have the most significant
role in clinical cases [3].
The Pgp molecule consists of two almost identical halves
connected by a 75 amino acid long intracellular linker region.
Both halves comprise six membrane spanning a-helices forming a
transmembrane domain (TMD) and a nucleotide binding domain
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(NBD). The two TMDs define the substrate binding sites and the
translocation pathway, allowing the protein to transport various
hydrophobic compounds out of the cells [4]. The overall energy
requirement of drug efflux is covered by ATP hydrolysis
conducted by the two NBDs (for possible models, see e.g. Senior
[5], Ambudkar et al. [6]).
Pgp is generally expressed in tissues having barrier functions
(e.g., in endothelial cells of the blood-brain barrier, in hepatocytes,
in epithelial cells of the kidney and the intestines) and it is
suggested to have an important role in protection of the body from
toxic substances [2,3,7]). However, the loss of the abcb1a/b genes
in mice (homologues of the human ABCB1 gene) is not
accompanied by major physiological consequences [8,9]; hence,
inhibition of Pgp molecules may be a plausible strategy of
overcoming drug resistance without serious side effects. The
classical pharmacological approach involves co-administration of
the cytotoxic compounds that are substrates of Pgp with pump
inhibitors, to increase the accumulation of the former into the
tumor cells. Unfortunately, Pgp inhibitors often induce unpredict-
able and intolerable pharmacokinetic interactions and toxicity
through inhibiting other drug transporters or cytochrome P450, by
changing the clearance and metabolism of the co-administered
chemotherapeutic agents [10–12]
Several monoclonal antibodies (mAb) recognizing extracellular
epitopes have been developed against Pgp. A few of them (e.g.,
MRK16, MRK17, MC57, HYB-241, and UIC2) are thought to
recognize discontinuous conformation sensitive epitopes. Upon
binding, these antibodies can partially inhibit Pgp mediated drug
transport in vivo and in vitro [13–16]. However, this inhibitory
effect is often weak [13–18], its extent may depend on the
transported substrate [15,17,18], and it is variable even in the case
of the same substrate according to general experience.
UIC2 is an IgG2a isotype mouse monoclonal antibody raised
against human Pgp. It recognizes a complex epitope involving at
least the first [19] and the third extracellular loops of the protein
[20]. In the absence of Pgp substrates and modulators UIC2 can
bind only to 10–40% of cell surface Pgps, while the rest adopts the
UIC2 binding conformation only in the presence of a distinct
group of substrates or modulators (e.g., cyclosporine A (CsA), SDZ
PSC 833, vinblastine and paclitaxel [21–23]. In previous studies
we have demonstrated that the UIC2 antibody itself completely
inhibits Pgp function when it is applied together with any of the
above Pgp modulators added at low, sub-inhibitory concentrations
[22]. The above phenomenon was also confirmed in vitro, by
measuring the cellular accumulation of various fluorescent Pgp
substrates including DNR, R123, calcein and a radioactive tracer
99mTc-Mibi [22]. In line with the above, combined treatment with
either CSA + UIC2 or paclitaxel + UIC2 specifically decreased the
rate of glucose metabolism in Pgp+ cells, as measured in 2-
[18F]fluoro-2-deoxy-D-glucose (18FDG) accumulation experi-
ments, also suggesting that Pgp inhibition with concomitant
decrease of energy consumption has occurred [23]. On the other
hand, we also demonstrated in xenotransplanted severe combined
immunodeficient (SCID) mice that UIC2 could readily penetrate
into the compact solid tumors, intensively staining cell surface
Pgps and increasing daunorubicin accumulation in the Pgp+
tumors to the level of the Pgp- ones [22].
In the present study we tested whether the combined treatment
with CsA and UIC2 mAb can potentiate the anti-tumor effect of
doxorubicin (DOX) in Pgp+ tumors to achieve clinically relevant
reduction in tumor size, applying the above experimental model
[22]. Tumor growth was followed by weighing the mass of the
tumors in sacrificed animals and also in vivo on the basis of 18FDG
accumulation. In the latter case a small-animal Positron Emission
Tomography (PET) camera was applied to visualize tumors on the
basis of their increased rate of glucose metabolism [24–26]. Our
data demonstrate that the combined application of a class of
modulators (including CsA) used at sub-inhibitory concentrations
and of the UIC2 antibody may serve as an effective tool for
blocking the growth of Pgp expressing tumors.
Materials and Methods
Ethics Statement
The experiments using human blood were done with the
approval of the Scientific and Research Ethics Committee of the
Medical Research Council (ETT TUKEB, permission number:
25364-1/2012/EKU (449/P1/12.)). Written informed consent
was obtained from donors prior to blood donation, and their data
were processed and stored according to the principles expressed in
the Declaration of Helsinki.
In animal experiments the Principles of Laboratory Animal Care
(National Institute of Health) was strictly followed, and the
experimental protocol was approved by the Laboratory Animal
Care and Use Committee of the University of Debrecen
(Permission Numbers: 26/2006/DE-MAB and 122/2009/DE-
MAB).
Cell Lines
KB-3-1 human epidermoid carcinoma cell line and KB-V1, its
Pgp positive counterpart were used in the experiments (obtained
from Michael Gottesman’s lab, NIH, Bethesda) [27,28]. The cells
were grown as monolayer cultures at 37uC in Dulbecco’s modified
Eagle’s medium (DMEM) containing 4.5 g/l glucose and supple-
mented with 10% heat-inactivated fetal bovine serum (FBS),
2 mM L-glutamine and 25 mM/ml gentamycin. The KB-V1 cells
were cultured in the presence of 180 nM vinblastine until 3 days
before their use. The viability of the cells in our experiments was
always higher than 90%, as assessed by the trypan blue exclusion
test. The cells were regularly checked for mycoplasma by the
Plasmo Test mycoplasma detection kit (San Diego, CA) and found
to be negative.
Chemicals
All the Pgp substrates, modulators, cell culture media and
supplements were from Sigma–Aldrich (Budapest, Hungary). The
UIC2, 15D3, 5D3 and QCRL-3 mAbs were purified from the
supernatants of hybridoma cell lines using affinity chromatogra-
phy. The hybridoma cell lines were purchased from the American
Type Culture Collections, Manassas, VA, USA), except the 5D3
hybridoma cell line, which was a kind gift from Brain P.
Sorrentino (Division of Experimental Hematology, Department
of Hematology/Oncology, St. Jude Children’s Research Hospital,
Memphis, Tennessee). The mAb preparations were.97% pure by
SDS/PAGE. The glucose analogue 2-[18F]fluoro-2-deoxy-D-
glucose (18FDG) was synthesized and labeled with the positron-
decaying isotope 18F according to Hamacher et al. [29].
Indirect immunofluorescence
For detection of Pgp and ABCG2 living cells (106 cells/ml) were
incubated in the presence of 30 mg/ml 15D3 anti- Pgp mAb or
2 mg/ml 5D3 anti-ABCG2 mAb for 30 min at 37uC. For
measurement of MRP1 (ABCC1) expression cells were fixed and
permeabilised with 1% para-formaldehyde and 0.1% TritonX-100
in PBS (15 min; 4uC) and then labeled with 2 mg/ml QCRL-3
mAb (30 min; 4uC). After two washes with ice-cold PBS
containing 1% bovine serum albumin (BSA-PBS), cells were
incubated with goat anti-mouse IgG (0.5 mg/ml CruzFluor 647
In Vivo Anti-Tumor Effect of UIC2 mAb
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(CFL647-GaMIgG), Santa Cruz Biotechnology, Inc., Texas) for
30 min at 4uC. Fluorescence intensities were detected using a
Becton Dickinson FACSAria III Cell Sorter (Becton Dickinson)
measuring the 633 nm/660620 nm fluorescence intensities.
Fluorescence signals were collected in logarithmic mode and the
cytofluorimetric data were analyzed by the BDIS CELLQUEST
(Becton Dickinson) software.
To detect Pgp expression in tumors 5-mm-thick cryosections
were prepared, dried at room temperature and fixed in pre-cooled
acetone (-20uC) for 10 min. Sections were then washed with PBS
and blocked with 1% BSA-PBS for 20 minutes to avoid non-
specific labeling and further incubated at room temperature with
the UIC2 (10 mg/ml) mouse mAb for 60 min. To visualize the
binding of the primary antibody an Alexa-488 conjugated goat
anti-mouse IgG (A488-GaMIgG, Invitrogen) was used at 1:1000
dilution. Negative controls were obtained by omitting the primary
antibody.
A Zeiss LSM 510 confocal laser-scanning microscope was used
for the measurements. Alexa-488 was excited at the 488 nm line of
an argon-ion laser. Fluorescence was detected through a 505–
550 nm band pass filter. Images of 5126512 pixels were obtained
in extended focus mode, through a 636 (numerical aperture = 1.4)
Plan-Apochromat oil immersion objective.
In vitro cytotoxicity tests
Cells were seeded in 96-well plates at a cell density of 56103
cells/well. 24 hours later DOX was added at different concentra-
tions with CsA and/or UIC2 mAb or the modulator alone, and
the plates were further incubated for 72 h at 37uC. The cell
viability was determined using the AlamarBlue assay (Serotec, UK)
measuring the 530/590 nm fluorescence intensity of the dye in an
automated microplate reader (BioTec Synergy HT, US). The
fluorescence intensities of the samples were normalized to the
fluorescence of the untreated (DOX, antibody and CsA free)
control sample, and plotted as a function of DOX concentration.
Dose-response curves were fitted, and EC50 values were calculated
by SigmaPlot 12.0 programme (Systat Software, Inc., USA).
In vitro antibody-dependent cell-mediated cytotoxicity
(ADCC) assay
ADCC experiments were performed as described previously
[30] with minor modifications. Human peripheral blood mono-
nuclear cells (PBMCs) were prepared from the blood of healthy
donors by Ficoll (Histopaque-1077, Sigma-Aldrich, Budapest)
density gradient centrifugation. The PBMC rich fraction (effector
cells) was washed three times and re-suspended in DMEM
containing 10% FCS. After trypsinization, KB-V1 and KB-3-1
(target cells) cells were labeled with 5(6)-carboxyfluorescein
diacetate N-succinimidyl ester (CFDA-SE) at a concentration of
10 mM at 37uC for 10 min. Then, the cells were washed thrice
with DMEM containing 10% FCS and 1% BSA to remove
unbound CFDA-SE and finally re-suspended in DMEM contain-
ing 10% FCS. 1.56105 target cells were mixed with effector cells
at target/effector cell ratios of 1:5, 1:10, 1:50 and 1:100 in a final
volume of 1 ml. Samples were incubated in the absence or
presence of 0.1 mM CsA and/or 20 mg/ml UIC2 at 37uC for
8 hours in CO2 incubator. After incubation the cells were washed
and then re-suspended in ice cold phosphate-buffered saline (PBS),
containing 8 mM glucose and 5 mg/ml propidium iodide (PI) and
were analyzed using a Becton Dickinson FACScan flow cytometer
(Mountain View, CA). The labeling distinguishes four populations
of cells as it is demonstrated in Fig. S1: 1. living target cells in
green (CFDA-SE positive cells); 2. dead target cells in green and
red (CFDA-SE and PI double positive cells); 3. dead effector cells
in red (PI positive cells), and 4. live effector cells, which remain
unstained. The negative control sample did not contain PBMCs,
while tumor cells killed by 4% para-formaldehyde served as the
positive control. The percentage of killed target cells was
calculated dividing the number of PI and CFDA-SE double
positive cells (dead cells) by the number of the CFDA-SE positive
cells.
In vitro complement-dependent cytotoxicity (CDC) assay
Samples containing 2.56105 KB-V1 or KB-3-1 cells and
20 mg/ml UIC2 mAb in the presence or absence of 0.1 mM CsA
were treated with freshly prepared human serum at different
dilutions in DMEM medium. The samples were incubated for
4 hours in CO2 incubator at 37uC and then stained with 5 mg/ml
PI. The percentage of the PI positive dead cell was determined by
a Becton Dickinson FACScan flow cytometer (Mountain View,
CA).
The hemolytic complement activity of the human serum
samples was determined applying sheep red blood cells sensitized
with a rabbit stroma antibody (SSRBC) kindly provided by Attila
Ba´csi (Inst. of Immunology, University of Debrecen, Faculty of
Medicine). 50 ml of 1% SSRBC was mixed with different dilutions
of human serum or heat inactivated human serum (inactivated at
56uC for 30 min) and incubated for 30 min at 37uC. After
centrifugation the absorbance of the supernatants was measured at
541 nm by BioTek Synergy HT plate reader. The HC50 value
where 50% of the RBCs were lysed was determined for the human
sera and found to be normal.
Animal model and study design
Adult (10 to 12 week-old), pathogen-free B-17 severe combined
immunodeficiency (SCID) mice were used in this study [31].
Animals were housed under pathogen free circumstances at a
temperature of 2662uC, with 50610% humidity and artificial
lighting with a circadian cycle of 12 h. The food and drinking
water (sterilized by autoclaving) were available ad-libitum to all
animals.
SCID mice were injected subcutaneously with KB-3-1 (Pgp-;
1.56106 cells in 150 ml sterile phosphate-buffered saline (PBS)) on
the left and KB-V1 (Pgp+; 36106 cells in 150 ml sterile PBS) cells
on the right thighs. To obtain approximately similar tumor sizes in
case of KB-V1 and KB-3-1 cells we had to inject double number
of KB-V1 cells, because of their slower cell proliferation rate. In
another experiment we grafted four tumors per animal in order to
limit the number of animals and to maximize the number of
tumors imaged. In this case each animal received two injections in
the shoulders and two in the upper part of the thighs. Tumors
were grown for 4 days and then the mice were treated with DOX
alone (5 mg/kg, i.v.), or DOX combined with either UIC2 mAb
(5 mg/kg, i.v.) or CsA (Sandimmun, Novartis, Basel, Switzerland;
10 mg/kg i.p.) or both. The animals were killed 8 days after
treatment with chemotherapy by cervical dislocation and the
tumors were removed to weigh them and then they were snap
frozen in liquid nitrogen and stored at -70uC till mRNA expression
analysis.
mRNA expression analysis
The frozen tumor sections were equilibrated in 10 volumes pre-
chilled RNAlater-ICE solution (Applied Biosystem, CA) at -20uC
overnight to protect RNA from degradation and then total RNA
was isolated using the RNeasy Mini kit (Qiagen Inc., CA)
according to the protocol. RNA quantity was determined by
NanoDrop ND-1000 UV-Vis Spectrophotometer (NanoDrop
Technologies, Wilmington, DE). RNA was then subjected to
In Vivo Anti-Tumor Effect of UIC2 mAb
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reverse transcription-real time quantitative polymerase chain
reaction (RT-qPCR) using the Taqman assay with stocked primers
and probes (Applied Biosystem, CA). Pgp mRNA expression was
normalized to the human glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) expression.
Small-animal PET imaging using 18FDG
After the implantation of tumor cells 18FDG PET scans were
repeated at different time points. Prior to PET measurements,
mice were fasted overnight. On the day of PET imaging mice were
pre-warmed to a body temperature of 37uC and this temperature
was maintained throughout the uptake and scanning period to
minimize the visualization of brown fat. Mice were injected via the
tail vein with 5.560.2 MBq of 18FDG. 40 min after tracer
injection animal were anaesthetized by 3% isoflurane with a
dedicated small animal anesthesia device and then 20 min long
static single-frame PET scans were acquired using a small-animal
PET scanner (MiniPET-II, Department of Nuclear Medicine,
Faculty of Medicine, University of Debrecen) to visualize the
tumors.
The MiniPET-II system is a dedicated small animal PET
scanner developed with the help of a Hungarian project. The
MiniPET-II scanner consists of 12 detector modules including
LYSO (Cerium Doped Lutetium Yttrium Orthosilicate) scintilla-
tion crystal blocks and position sensitive photo multiplier tubes.
Each crystal block comprises 35635 pins of 1.2761.27612 mm
size. Scanner normalization and random correction were applied
on the data and the images were reconstructed with the standard
maximum likelihood expectation maximization iterative algo-
rithm. The pixel size was 0.2760.2761.35 mm and the spatial
resolution varies between 1.4 to 2.1 mm from central to 25 mm
radial distances. The system sensitivity is 11.4%.
18FDG-PET data analysis
The 18FDG uptake was expressed in terms of standardized
uptake values (SUVs) and tumor to muscle (T/M) ratios.
Ellipsoidal 3-dimensional regions of interest (ROI) were manually
drawn around the edges of the tumor xenografts by visual
inspection using BrainCad software (Institute of Nuclear Medicine,
University of Debrecen). The standardized uptake value (SUV)
was calculated as follows: SUV= [ROI activity (Bq/ml)]/[injected
activity (Bq)/animal weight (g)], assuming a density of 1 g/cm3.
The T/M ratios were computed as the ratio of the mean activity in
the tumor volume of interest (VOI) and the background (muscle)
VOI.
Statistical analysis
The displayed data are the means 6 SD of the results of at least
three independent experiments. Data have been analyzed using
SigmaPlot 12.0 programme (Systat Software, Inc., USA) and IBM
SPSS Statistics 20 (IBM Corp., USA). Statistical significance was
assessed using analysis of variance (ANOVA), applying Holm-
Sidak method for post hoc pair-wise comparison of the different
samples. In the case of unequal variances Dunnett T3 post hoc
pair-wise comparison method was used. Differences were consid-
ered to be significant at P,0.05.
Results
In vitro cytotoxicity measurements
KB-V1 cells express Pgp at high level, while other drug
transporting ABC proteins ABCG2 and ABCC1 were not
detectable by means of indirect immunofluorescence and flow
cytometry (Fig. S2). KB-3-1 cells do not express any of the above
ABC transporters at measurable level (Fig. S2). In accordance with
the high Pgp expression level of KB-V1 cells the EC50 value of
DOX was 2.1960.39 mM in these cells, while it was only
4463 nM in KB-3-1 (Pgp-) cells (Fig. 1). In KB-V1 cells CsA
co-treatment decreased the EC50 value of DOX in a dose
dependent manner, while UIC2 had only a weak, statistically not
significant effect. Interestingly, the combined treatment of KB-V1
cells with 1 mM CsA and a saturating concentration of UIC2 mAb
decreased the EC50 value to 33619.7 nM, which could be
achieved by 10 times higher CsA concentration when it was
applied alone (Fig. 1). In contrast, administration of the UIC2
mAb and 1 mM CsA to cultures of KB-3-1 cells, simultaneously or
alone, had no significant effects on their DOX sensitivity.
mRNA expression analysis of Pgp in the tumor xenografts
and cells used for grafting the tumors
Based on the above in vitro results, we have designed in vivo
experiments to test the effectiveness of the combined treatment
with low dose of CsA, UIC2 and DOX. SCID mice were
inoculated with KB-V1 and KB-3-1 cells, respectively. Palpable
subcutaneous tumors developed in 10–12 days. Their Pgp
expression was compared to that of the tumor cells used for
grafting the tumors. Since the immunofluorescence intensities in
frozen tissue sections and cell monolayers are not directly
comparable, Pgp expression was examined at the mRNA level.
In the KB-3-1 tumors a well detectable ,60-fold increment of Pgp
mRNA levels occurred compared to the inoculated cells, while the
Pgp mRNA level of the KB-V1 tumors did not change upon
proliferation of the inoculated cells (Fig. 2). The Pgp mRNA levels
proved to be at least three orders of magnitude higher in the KB-
V1 tumors compared to the KB-3-1 xenografts (see Fig. 2). Thus,
the KB-V1 tumor xenografts retained their MDR phenotype as it
was also proved by indirect immunofluorescent labeling (see Fig.
S3), while the KB-3-1 cells continued to express Pgp at very low
levels (not detectable by immunofluorescence, Fig. S3) in the
developed tumors on the time scale of the in vivo experiments.
18FDG accumulation in xenotransplanted tumors
Grafted tumors were grown for 4 days, then the mice were
treated with DOX alone (5 mg/kg, i.v.) or DOX combined with
either the UIC2 mAb (5 mg/kg, i.v.) or CsA (10 mg/kg, i.p.), or
Figure 1. Cytotoxic effect of DOX in KB-3-1 (Pgp-; grey bars)
and KB-V1 (Pgp+; empty bars) cells and its potentiation by
treatments with CsA (used at the indicated concentrations)
and/or UIC2 mAb (20 mg/ml). EC50 values were calculated by fitting
the dose-response curves. Values are means (6 SD) of 3 independent
experiments. Statistically significant differences are shown by * (P,
0.05).
doi:10.1371/journal.pone.0107875.g001
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both. For an in vivo visualization of their effects, miniPET-18FDG
accumulation measurements were performed, carrying out the
scans 6–8 days after the above treatments. Fig. 3 shows
representative 18FDG accumulation scans and the anatomical
pictures of untreated (Fig. 3A and C) and DOX-UIC2-CsA
treated (Fig. 3B and D) SCID mice bearing Pgp+ (KB-V1, right
shoulder and thigh) and Pgp- (KB-3-1, left shoulder and thigh)
tumor xenografts. At the time of the measurements the tumors of
untreated mice were 5–8 mm in diameter (6.4361.13 mm mean
6 SD, KB-3-1; 6.061.15 mm mean 6 SD, KB-V1), and well-
detectable on the basis of their increased rate of glucose
metabolism.
The tumor (T) to skeletal muscle (M) 18FDG accumulation ratio
(T/M) was 4.260.6 in the case of Pgp- and 4.860.7 for the Pgp+
tissues (n = 7, 6 SD), indicating significantly higher rate of glucose
consumption in tumors compared to the muscle cells in both cases.
No visible or palpable tumors developed in 20% of the animals
treated with the combination of DOX-UIC2-CsA. This observa-
tion was confirmed by the mini-PET scans, since no significant
18FDG accumulation was observed at the sites of tumor cell
inoculation in these animals, as reflected by the T/M 18FDG
accumulation ratios being close to 1 (T/M=1.160.2 for Pgp+ and
T/M=0.9760.1 for Pgp- tumors; (n = 4)).
Effect of DOX treatment combined with UIC2 and/or a
low dose of CsA on the weights of grafted tumors
Eight days after chemotherapy, the animals were sacrificed by
cervical dislocation and the tumors were removed to weigh them.
As it is shown in Fig. 4A, DOX treatment alone was almost
ineffective in the case of KB-V1 tumors, while the weight of the
KB-3-1 tumors decreased considerably. Co-administration of
10 mg/kg CsA decreased the size of the KB-V1 tumors only
mildly and did not affect the KB-3-1 tumors. Combined treatment
with DOX-CsA-UIC2 decreased the mean weight of the KB-V1
tumors 9 fold compared to the animals treated with DOX alone.
The combined treatment also decreased the mean weight of the
KB-3-1 tumors, but not in a statistically significant extent.
Importantly, only 52% of the grafted Pgp+ or Pgp- tumors
developed into detectable tumors in the DOX-CSA-UIC2 treated
animals (see Fig. 4B), and 20% of the animals remained
completely tumor-free. In contrast, we always detected tumors in
the other treatment groups. Co-administration of UIC2 and DOX
also decreased tumor size significantly compared to DOX alone in
the case of KB-V1 tumors. This finding, in view of the fact that
UIC2 treatment alone does not affect the EC50 value of DOX in
in vitro cytotoxicity tests (Fig. 1), suggested to us that the growth
inhibitory effect of the antibody is not exclusively due to Pgp
inhibition. UIC2 binding did not affect the in vitro cell viability
significantly (Fig. 5); therefore, the contribution of the immune
system, that is partly functional in the SCID mice, was tested.
In vitro ADCC and CDC measurements
Fig. 6 shows the effect of human peripheral blood mononuclear
cells (PBMCs), and of human serum samples, on UIC2 mAb
treated KB-V1 and KB-3-1 cells, in vitro. PBMCs killed about 70-
80% of the UIC2 treated KB-V1 cells both in the presence and
absence of CsA, at target to effector cell ratios of 1:50 and 1:100,
respectively (Fig. 6A), in contrast with the UIC2 treated KB-3-1
cells that exhibited a survival rate similar to that of the untreated
control (Fig. 6B). In the absence of UIC2, the percentages of dead
target cells were low (see Fig. 6A and B).
In order to assess the possible role of CDC in UIC2 mediated in
vivo tumor cell killing, the cytotoxicity of human serum samples
Figure 2. Relative Pgp mRNA expression levels of the KB-V1
and KB-3-1 tumors and the cells applied for grafting the
tumors. Pgp expression levels are normalized to the expression level of
GAPDH mRNA (mean 6 SD, n = 5). The Pgp expression levels of
inoculated KB-V1 cells and tumors were significantly different from
those of the KB-3-1 cells and tumors (P,0.01), while the Pgp expression
levels of tumors were not statistically different from those of the cells
they originated from.
doi:10.1371/journal.pone.0107875.g002
Figure 3. Effect of combined treatment with DOX+CsA+UIC2 on
the KB-V1 and KB-3-1 tumors visualized in vivo by 18FDG-
miniPET. Coronal section of 18FDG-miniPET image of a representative
control (A) and a DOX-CsA-UIC2-treated tumor bearing mouse (B).
Standardized uptake values (SUV) are calculated as described in
Materials and Methods. The sites of tumor cell inoculation are shown
by arrows (KB-V1 tumors, right side arrows; KB-3-1 tumors, left side
arrows). Below: autopsies of the same control (C) and treated (D)
animals. Bar: 10 mm.
doi:10.1371/journal.pone.0107875.g003
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was measured in vitro. Cell killing did not increase in the UIC2
treated KB-V1 (Fig. 6C) and KB-3-1 (Fig. 6D) samples despite the
strong hemolytic activity of the applied sera (Fig. 6D, inset).
Discussion
In the present experiments SCID mice xenotransplanted with
Pgp+ and Pgp- tumors were used to study the efficacy of an
antibody-based multidrug resistance reversal strategy. The KB-
V1/KB-3-1 cell pair does not express ABCG2 and MRP1
(ABCC1) at detectable levels, while the KB-V1 cells have high
Pgp expression level (see Fig. S2 and Fig. 2). They are growing fast
and develop into subcutaneous tumors of ,1 cm diameter in
about 10-12 days after inoculation of 1–36106 cells into the
animals. An advantage of the fast tumor growth in this model
system is that the Pgp expression level of the tumor cells does not
decline in the absence of Pgp substrates (see Fig. 2) on the time
scale of the in vivo experiments.
In the above model system, co-treatment with UIC2 + CsA
potentiated the anti-tumor effect of DOX and inhibited or
hindered the development of KB-V1 Pgp+ tumors in vivo (Fig. 4).
At the same time, DOX treatment alone did not have a significant
effect on the size of the KB-V1 tumors. These data are in line with
the conclusions of our previously published in vitro and in vivo
drug accumulation studies [22] and with the results of the in vitro
cytotoxicity measurements shown in Fig. 1. Although these
observations may suggest that the dramatic antitumor effect of
the combined treatment is the result of increased antibody binding
with consequential Pgp inhibition and DOX accumulation, the
mechanism proved more complex.
SCID mice have intact complement system as well as
functioning macrophages, natural killer cells and polymorphonu-
clear cells [32]. Therefore, antibody binding to the tumor cells
may elicit cytotoxicity directly through complement binding
(complement-dependent cytotoxicity, CDC) or indirectly, via the
recruitment of the above effector cells to the antibody covered
tumor cells (antibody-dependent cell-mediated cytotoxicity,
ADCC). The possibility, that immunological factors contribute
to the cytotoxic effect of our treatment protocol is strongly
supported by the difference between the outcomes of in vitro
cytotoxicity measurements and of the in vivo experiments
conducted in SCID mice (compare Fig.1 and Fig. 4). In the in
vitro cytotoxicity assay, UIC2 alone only mildly aggravated DOX
cytotoxicity (see Fig. 1) what could be explained by the trapping
and inhibition of only a small fraction of cell surface Pgps by UIC2
in the absence of CsA [22]. In contrast, we experienced in vivo a
marked decrease of tumor size in response to the DOX+UIC2-
only treatment, as the average weight of the KB-V1 tumors was
approx. 4 fold smaller compared to the animals treated with DOX
alone (Fig. 4A). These data are in line with the positive results of
our in vitro ADCC assays (Fig. 6), supporting the notion that the
UIC2 mAb also induces ADCC in vivo in the SCID mice.
The involvement of ADCC in the in vivo anti-tumor effect of
UIC2 treatment is an unexpected finding of our experiments, since
IgG2 antibodies are mostly inefficient at supporting effector
functions and are chosen for antibody therapy when effector
functions are unnecessary or undesirable [33]. However, there is
an example [34] when the antitumor and antimetastatic effects of
two IgG2 isotye anti-Pgp antibodies (the mouse-human chimeric
Ab (MH162) and its mouse counterpart (MRK16)) was attributed
Figure 4. Effect of treatment with DOX combined with UIC2
and/or a low dose of CsA on the weights of the grafted tumors
(A) and on the percentage of the detectable tumors in the
different treatment groups (B). Tumor weights were expressed as a
percentage of the average weight of the tumors of untreated animals
measured at the time of the termination of the experiment (mean
values 6 SEM, n = 8). Statistically significant differences relative to the
untreated control and the DOX-only treated groups are marked with *:
P,0.05; **: P,0.01; ***: P,0.001). Grey bars: KB-3-1 (Pgp-) and empty
bars: KB-V1 (Pgp+) tumors.
doi:10.1371/journal.pone.0107875.g004
Figure 5. Effect of the UIC2 mAb treatment on the in vitro
viability of KB-3-1 (Pgp-; grey bars) and KB-V1 cells (Pgp+;
empty bars) in the presence or absence of 1 mM CsA. Cell
viability was expressed as percentage of the untreated control. Values
are means (6 SD) of three independent experiments.
doi:10.1371/journal.pone.0107875.g005
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to ADCC. Similarly, it was proven in a recent study that a human
IgG2 isotype mAb specific for epidermal growth factor receptor
effectively triggers ADCC by recruting monocytes and neutrophils
[35] via FccRIIa binding [36,37]. Since IgG2 isotype antibodies
do not trigger natural killer cell mediated ADCC [35], therefore in
our in vitro ADCC experiments carried out with PBMCs cell
killing was mediated by monocytes. Since SCID mice also have
monocytes [32] the same mechanism is functional and probably
explains our in vivo results.
The strong anti-tumor effect of the combined treatment might
be attributed exclusively to ADCC triggered by the UIC2 mAb
binding. However, the fact that the extents of the in vitro ADCC
effects were indistinguishable in the presence of UIC2 or UIC2+
CsA suggests that binding of the antibody to a small fraction of the
cell surface Pgps (20-40%) is sufficient to induce a maximal ADCC
effect (Fig. 6A). Consequently, the differences in the size of the
KB-V1 tumors between the UIC2 and UIC2+CsA treated animals
and the lack of the KB-V1 tumors in 52% of these animals (Fig 4A
and B) argue against the above assumption and suggests that the
stronger Pgp inhibitory effect of the UIC2+CsA combination
mediates the anti-tumor effect at least in part. Pgp inhibition by
the antibody requires saturating antibody concentrations that
seems to be reached in our experiments, since strong UIC2
staining and a two fold increase in the accumulation of a Pgp
substrate daunorubicin was measured in the tumor sections
prepared from the tumors 8 hours after the injection of UIC2
and CsA [22] added at similar conditions. Taken together, our in
vitro and in vivo data suggest that strong anti-tumor effect can be
reached by the combinative treatment studied, as a joint result of
Pgp inhibition and ADCC. However, the relative contribution of
these mechanisms to the anti-tumor effect of the UIC2 mAb is not
known.
ADCC can be triggered at relatively low receptor occupancy by
the antibody or at low receptor abundance [35,38]. Thus, the 60
fold increased Pgp expression level of the KB-3-1 tumors
compared to the KB-3-1 cells (see Fig. 2.) is probably sufficient
to trigger ADCC effect, when the Pgp molecules are saturated by
the antibody in the presence of CsA. In line with this assumption
in 52% of the DOX-UIC2-CsA treated animals we could not
detect KB-3-1 tumors, while they appeared in all of the DOX or
DOX+UIC2 treated animals (see Fig. 4B).
It could be a limitation of our study that only one cell line pair
was used in the experiments. However, the observed effects have
been proven to be Pgp specific, since decreased tumor size was
detected exclusively in those animal groups that received UIC2
mAb treatment. In addition, in our previous studies we compared
the KB-V1 cell line with mdr1 transfected NIH 3T3 murine
fibroblast cells [22], and Pgp+ A2780AD ovarian carcinoma cells
[23] and found them equivalent in every aspect of their multidrug
resistant phenotype including the inhibition of Pgp-mediated drug
transport by UIC2 mAb. On the other hand, ADCC effect is not
dependent on the tissue origin of the target cells; rather it is
determined by the interaction between the Fc part of the antibody
and the Fc receptor of the effector cells.
Doubts about the possible clinical application of an anti-Pgp
mAb based tumor therapy are related to the likely side effects that
Figure 6. Antibody-dependent cell-mediated cytotoxicity (ADCC, panels A and B) and complement mediated lysis (CDC, panels C and
D) induced by UIC2 mAb treatment in vitro. In the ADCC assay KB-V1 (A) and KB-3-1 (B) tumor cells were labeled with CFDA-SE then mixed with
PBMCs freshly isolated from peripheral blood at different target to effector cell ratios. Samples were treated with 10 mM CsA (#), 20 mg/ml UIC2 mAb
(&), 10 mM CsA and 20 mg/ml UIC2 mAb (%) or buffer (N). After 8 h incubation at 37uC, samples were stained with PI and analyzed by flow
cytometry. In the CDC assay, cells were incubated with human serum at different dilutions for 4 h. Inset of panel C: Hemolytic effect of the serum (m)
and of heat inactivated serum (n) on sensitized sheep red blood cells served as positive and negative control, respectively. The percentages of killed
cells were calculated as described in Materials and Methods. Values are means (6 SD) of four independent experiments, ***P,0,001.
doi:10.1371/journal.pone.0107875.g006
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may arise as a result of either Pgp inhibition or ADCC, both
exerted on cells expressing Pgp at physiological barriers of the
body. For instance, inhibition of Pgp expressed in the blood-brain
barrier may lead to increased accumulation of its substrates in the
central nervous system leading to neurotoxicity, as it was
experienced in mdr1a/b knock-out mice [8]. However, adminis-
tration of Pgp modulators in clinical trials does not seem to cause
toxicity to the central nervous system [39] probably because other
ABC transporters (e.g. MRP1, BCRP1) may compensate for the
loss off Pgp’s gatekeeper function in the blood-brain barrier
[40]. However, in contrast to Pgp inhibition, ADCC may
damage the tissues at the physiological Pgp expression sites. Our
in vitro assays using human PBMCs confirmed that UIC2 mAb
effectively triggers ADCC. Since ADCC is mediated via the Fc
portion of the antibody, to avoid this side-effect upon human
applications the whole UIC2 antibody could be substituted for
by its Fab fragments (that behave very similarly to whole
antibodies in vitro; our unpublished data) or upon humanization
of the antibody its effector functions may be fine-tuned by the
design of the Fc part [33]. However, it remains to be studied if
inhibition of Pgp function alone may augment DOX cytotox-
icity sufficiently enough for a therapeutically significant anti-
tumor effect.
The UIC2 mAb does not bind to mouse Pgp [14], therefore the
SCID mouse model system is not applicable for studying the
possible side effects brought about by antibody binding to
physiological Pgp expression sites. Since the UIC2 mAb also
recognizes primate [14] and sheep [41] Pgp, such animal models
may be used for the evaluation of the feasibility of the strategy
demonstrated herein. Direct injection of the antibody into the
tumor tissue may also be tested for the purposes of reducing
antibody dose and decrease systemic side effects.
In our model system, treatments were applied shortly (four days)
after injection of the tumor cells, when the tumors were still rather
small, a situation perhaps analogous to the clinical setting when
systemic therapy is applied to prevent or hinder the development
of multidrug resistant primary or metastatic tumors.
Each multidrug resistant tumor may have a unique signature
of resistance mechanisms. Consequently, cancer therapy will
need to be personalized, not only with respect to the
mechanisms of malignant transformation but also regarding
the mechanisms of resistance [42]. The strategy of Pgp
inhibition demonstrated herein is offered to enrich the repertoir
of possible protocols that can be considered for the treatment of
multidrug resistant tumors, once humanized UIC2 becomes
available.
Supporting Information
Figure S1 In the ADCC assay KB-V1 (panels A, B, C) and
KB-3-1 (D, E, F) tumor cells were labeled with CFDA-SE,
then mixed with PBMCs freshly isolated from periph-
eral blood at 1:5 (B, E) or 1:100 (C, F) target to effector
cell ratios. Samples were treated with 20 mg/ml UIC2 mAb.
After 8 h incubation at 37uC, samples were stained with PI and
analyzed by flow cytometry. Green gates mark living target cells,
while red gates show dead target cells.
(TIF)
Figure S2 Flow cytometric analysis of Pgp, ABCG2 and
MRP1 expression in KB-V1 (A, C, E) and KB-3-1 (B, D, F)
cell lines applying indirect immunofluorescence stain-
ing by CFL647-conjugated GaMIgG. Pgp was detected by
15D3 mAb, while ABCG2 and MRP1 (ABCC1) were labeled by
5D3 and QCRL-3 mAbs, respectively. Grey filled histograms
show antibody untreated cells, while dashed lines represent
samples treated with secondary antibody only. The ABCG2
positive MDCK ABCG2 cells (G) and the MRP1 (I) expressing
GLC4-ADR cell line and their nonexpressing counterparts (H and
J) were used as controls. The GLC4 human small cell lung
carcinoma cell line pair was a kind gift from Pinedo HM
(Department of Medical Oncology, Academic Hospital Vrije
Universiteit, Amsterdam), while the MDCK (Madin-Darby canine
kidney) cell line and its ABCG2 transfected counterpart was kindly
provided by Sarkadi B (Biomembrane Institute of Molecular
Pharmacology, Budapest)
(TIF)
Figure S3 Pgp expression of KB-V1 (A) and KB-3-1 (C)
tumor xenografts visualized by indirect immunofluores-
cence. Panels (B) and (D) are phase contrast images of the same
tumor slices. The 5 mm thick cryosections were fixed in acetone,
labeled with UIC2 mAb followed by A488-GaMIgG at room
temperature for 60 min.
(TIF)
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